¼¿ï¾Æ»êº´¿ø Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À° : 2023-06-10
±³À°ÀÏÀÚ : 2023-06-10
±³À°Àå¼Ò : ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç
±³À°ÁÖÁ¦ : Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ¼¿ï¾Æ»êº´¿ø
´ã´çÀÚ : ¿ì¹Ì°æ
¿¬¶ôó : 02-3010-4560
À̸ÞÀÏ : rainmk@rainmk@amc.seoul.kr
±³À°Á¾·ù : º´¸®°ú
Âü¼®¿¹»óÀÎ : 90¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í "1. Àü°øÀÇ/±ºÀÇ°ü/¿¬±¸¿ø »çÀüÁ¢¼ö 20,000¿ø ÇöÀåÁ¢¼ö 30,000¿ø
2. Àü¹®ÀÇ /¹Ú»ç »çÀüÁ¢¼ö 40,000¿ø ÇöÀåÁ¢¼ö 50,000¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 10:00~10:40 Clinical Application of ctDNA in Medical Oncology ±è»óÀ§(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 10:40~11:40 Strategic development of anti-cancer immunotherapy using single cell RNA sequencin ÀÌÇý¿Á(°¡Å縯´ëÇб³)
½Ä»ç 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 11:40~13:10 Á¡½É ()
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 13:10~13:40 Liquid Biopsy based Clinical NGS at ASAN Pathology õ¼º¹Î(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 13:40~14:10 The age of whole genome sequencing: ready yet in clinics? ¼ºÃ¢¿Á(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 14:10~14:40 Longitudinal NGS analysis and early drug development À±½Å±³(¼¿ï¾Æ»êº´¿ø)
ÈÞ½Ä 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 14:40~15:00 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 15:00~15:30 Digging out useful information through NGS in cancer of unknown primary setting ±èÁöÈÆ(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 15:30~16:00 Clinical significance of concurrent genomic alterations in EGFR-mutant lung adenocarcinoma ȲÈñ»ó(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 16:00~16:30 Detection and interpretation of non-canonical fusions ¼ÛÀÎÇý(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°´ç 16:30~17:00 Efforts to utilize clinical NGS data in AMC ±è´öÈÆ(¼¿ï¾Æ»êº´¿ø)